Continuous remifentanil for pediatric neurosurgery patients

John W. German, Rajesh Aneja, Christopher Heard, Mark Dias

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Objective: Remifentanil hydrochloride is a new titratable opioid agonist with rapid onset and offset of action. We present 2 cases of intracranial mass lesions in whom remifentanil was used to obtain serial neurological examinations. Methods: Patients received bolus doses of remifentanil 1 μg/kg followed by continuous infusions of 0.1-0.5 μg/kg/min, titrated to effect. After the clinical examination, the remifentanil was restarted to the desired effect. Conclusion: The ultra-short duration of action of remifentanil makes it ideally suited for selected pediatric neurosurgical patients in whom frequent, serial neurological examinations are necessary. There were no side effects associated with the use of remifentanil.

Original languageEnglish (US)
Pages (from-to)227-229
Number of pages3
JournalPediatric Neurosurgery
Volume33
Issue number5
DOIs
StatePublished - Dec 1 2000

Fingerprint

Neurosurgery
Pediatrics
Neurologic Examination
Opioid Analgesics
remifentanil

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Surgery
  • Clinical Neurology

Cite this

German, John W. ; Aneja, Rajesh ; Heard, Christopher ; Dias, Mark. / Continuous remifentanil for pediatric neurosurgery patients. In: Pediatric Neurosurgery. 2000 ; Vol. 33, No. 5. pp. 227-229.
@article{8ed8994b848c46ef9cce2ed9edfc03bd,
title = "Continuous remifentanil for pediatric neurosurgery patients",
abstract = "Objective: Remifentanil hydrochloride is a new titratable opioid agonist with rapid onset and offset of action. We present 2 cases of intracranial mass lesions in whom remifentanil was used to obtain serial neurological examinations. Methods: Patients received bolus doses of remifentanil 1 μg/kg followed by continuous infusions of 0.1-0.5 μg/kg/min, titrated to effect. After the clinical examination, the remifentanil was restarted to the desired effect. Conclusion: The ultra-short duration of action of remifentanil makes it ideally suited for selected pediatric neurosurgical patients in whom frequent, serial neurological examinations are necessary. There were no side effects associated with the use of remifentanil.",
author = "German, {John W.} and Rajesh Aneja and Christopher Heard and Mark Dias",
year = "2000",
month = "12",
day = "1",
doi = "10.1159/000055959",
language = "English (US)",
volume = "33",
pages = "227--229",
journal = "Pediatric Neurosurgery",
issn = "1016-2291",
publisher = "S. Karger AG",
number = "5",

}

Continuous remifentanil for pediatric neurosurgery patients. / German, John W.; Aneja, Rajesh; Heard, Christopher; Dias, Mark.

In: Pediatric Neurosurgery, Vol. 33, No. 5, 01.12.2000, p. 227-229.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Continuous remifentanil for pediatric neurosurgery patients

AU - German, John W.

AU - Aneja, Rajesh

AU - Heard, Christopher

AU - Dias, Mark

PY - 2000/12/1

Y1 - 2000/12/1

N2 - Objective: Remifentanil hydrochloride is a new titratable opioid agonist with rapid onset and offset of action. We present 2 cases of intracranial mass lesions in whom remifentanil was used to obtain serial neurological examinations. Methods: Patients received bolus doses of remifentanil 1 μg/kg followed by continuous infusions of 0.1-0.5 μg/kg/min, titrated to effect. After the clinical examination, the remifentanil was restarted to the desired effect. Conclusion: The ultra-short duration of action of remifentanil makes it ideally suited for selected pediatric neurosurgical patients in whom frequent, serial neurological examinations are necessary. There were no side effects associated with the use of remifentanil.

AB - Objective: Remifentanil hydrochloride is a new titratable opioid agonist with rapid onset and offset of action. We present 2 cases of intracranial mass lesions in whom remifentanil was used to obtain serial neurological examinations. Methods: Patients received bolus doses of remifentanil 1 μg/kg followed by continuous infusions of 0.1-0.5 μg/kg/min, titrated to effect. After the clinical examination, the remifentanil was restarted to the desired effect. Conclusion: The ultra-short duration of action of remifentanil makes it ideally suited for selected pediatric neurosurgical patients in whom frequent, serial neurological examinations are necessary. There were no side effects associated with the use of remifentanil.

UR - http://www.scopus.com/inward/record.url?scp=0034513582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034513582&partnerID=8YFLogxK

U2 - 10.1159/000055959

DO - 10.1159/000055959

M3 - Article

C2 - 11155057

AN - SCOPUS:0034513582

VL - 33

SP - 227

EP - 229

JO - Pediatric Neurosurgery

JF - Pediatric Neurosurgery

SN - 1016-2291

IS - 5

ER -